ItalyThe World Health Organization (WHO) has issued updated guidelines regarding the use of the Ervebo® vaccine during the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC), which is caused by the Bundibugyo virus (BDBV). As of September 1, 2026, over 6,000 cases and more than 3,000 deaths have been reported, with Ituri province being the hardest-hit area. The WHO notes that while the Ervebo® vaccine is effective against the Ebola virus (EBOV), its efficacy against BDBV remains uncertain. The organization advises against the programmatic use of the vaccine for BDBV unless within a controlled research setting. The WHO emphasizes the importance of continuing established outbreak control measures alongside any potential vaccine use.
Bias read (Center): The article presents factual information about the WHO’s stance on the use of the Ervebo® vaccine for the BDBV outbreak without overtly favoring any political agenda. It provides balanced reporting on the scientific uncertainty surrounding the vaccine’s effectiveness against the new strain and the W
